Next Phase Newsletter

A firm based in Taiwan invests from an evergreen fund, and is a multi-stage investor, with investments made from seed stage all the way to IPO. The firm invests both in Taiwan and internationally, including in the US and Canada.  Investments are typically of $500,000-2 million.

The firm invests in a variety of sectors including medical devices, therapeutics, and digital health/AI.  The firm prefers to invest in companies with a pipeline of multiple assets rather than in single asset companies.  For therapeutics, the firm looks internationally for novel assets: within Taiwan, the firm focuses on repurposed drugs.

The firm prefers to invest in companies that already have a complete team.  For medical device companies, this must include commercial/sales staff.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A leading healthcare venture capital firm with multiple offices in USA invests in transformative biotechnology, medical technology, and health solutions companies seeking to improve clinical outcomes, enhance quality of life, and drive efficiency of healthcare delivery. The firm invests in both privately held and publicly traded companies through a variety of investment approaches.

The firm has raised nearly $2 billion in capital commitments and is investing from a fourth core fund of $585 million. The firm makes both venture-stage and growth-stage equity investments, which are typically in the $10-30 million range. The firm primarily invests in North America and Europe but may also consider opportunities in the Middle East.

The firm invests in biotechnology, medical technology, diagnostics, healthcare services, and healthcare IT. The firm is generally agnostic regarding indications. The firm invests across a range of stages, from development through profitability, but prefers to back technologies that have attained proof of concept data.

The firm invests in both pre-revenue companies and post-revenue companies. The firm typically leads or co-leads investments, and prefers to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A single family office based in the USA actively invests in pre-seed and seed-stage companies, and occasionally invests in Series A rounds as well. The firm is open to global companies, including those in emerging countries.

The firm is most interested in therapeutics opportunities and in terms of indication, the firm is most interested in oncology and CNS. The firm is open to various modalities but has mostly looked at small molecule and some peptide drugs. In addition, the firm is also interested in repurposed assets that have initially been shelved by big pharma. In terms of stage of development, the firm will look at pre-clinical and early clinical opportunities. The firm is also interested in diagnostics and some digital health. Their interests in healthtech include technologies that help health systems reduce costs, B2C products in mental health (especially pediatric) and chronic disease, and more.

The firm does not have specific company or management team requirements. The firm prefers to co-invest alongside likeminded investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm headquartered in Europe with offices throughout USA and Europe is investing out of its first fund and makes both seed/venture and growth stage investments ranging from $500k – $20M. The firm typically prefers straight equity investments, but will also consider convertible note financings. The firm has a fairly broad mandate, and invests evenly among enterprise software, fintech, consumer and digital health sectors. The fund’s LPs are large insurance companies, and along with capital, the firm looks to add value by providing portfolio companies direct introductions to these groups to help scale and realize their potential.

The firm plans to have digital health companies make up roughly 25% of its portfolio and will invest in consumer and B2B healthcare IT and tech-enabled health services. It is a requirement that the technology has utility for payers and providers. Some of the firm’s digital health portfolio companies include a behavior change platform that partners with insurers, Accountable Care Organizations (ACO) and Self-insured employers to provide research-based behavioral incentives for members to better manage their chronic conditions.

The firm invests in early-stage companies with annual revenues under $5M as well as growth stage companies with annual revenues exceeding $5M. The firm will consider pre-revenue companies with strong management teams and previously successful entrepreneurs. The firm invests globally.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture and growth capital firm provides expertise and funding to entrepreneurs and companies with global ambitions in life sciences and information technologies. The firm is based in Europe and focuses on early to growth and expansion stage including spin-offs and restarts. The firm prefers to be the lead investor and possibly co-lead. The firm seeks to allocate €7-15 million (in equity) per company through subsequent rounds of investment. The firm seeks to invest in companies that are based in the US and Europe. The firm is actively seeking new investment opportunities.

In the life sciences, the firm seeks to invest in medical devices and digital health. The firm is opportunistic in terms of subsectors and indications. Medical devices with a therapeutic focus are of high interest. The firm seeks growth stage companies with early sales or with products that, at minimum, have regulatory approval (CE mark) and compelling clinical data.

The firm requests a board seat in each portfolio company and generally holds a significant minority stake. The firm seeks a company with a strong management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private equity/venture capital company founded in 2001 and headquartered in the USA makes growth equity investments ranging from approximately $10 to $40 million over the investment’s lifetime. The firm primarily invests within the United States but is open to consider international investment as well.

The firm is currently looking for commercial stage companies in areas of medical technology and devices, life science instruments and tools, healthcare IT, healthcare services, agriculture and animal health.

The firm only invests in companies with commercial revenue. The firm supports organic growth strategies, which allow for gross profit growth and investment in product pipelines and commercial expansion. The firm looks to take a seat on the company board and prefers to be the lead or sole institutional investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early stage fund focused on angel investment and incubation in the healthcare field is currently investing from a fund backed by six major Chinese companies. The firm’s typical investment size range from USD 1-1.5 M and is open to leading or co-investing. The firm is currently seeking opportunities in China or US-based companies with a China angle.

The firm is looking for cutting edge platform technologies in sectors including therapeutics, medical devices, and diagnostics. The firm is agnostic to therapeutic indications. In terms of development stage, the firm focuses on startup teams with some preclinical validation.

The firm is looking for strong management teams with sector expertise. The firm aims to bridge between R&D and commercialization with a focus on China-based startup teams or US companies with a China angle. The firm may request a board seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.